Volume No : (2017) Volume: 05 Issue : 26 Year : 2017 Page No: 90-93
Authors : Hemalatha S., Balapriya P. Thasneem Banu S.
Abstract :
Extended-spectrum β-lactamases (ESBL) producing organisms pose a major problem for clinical therapeutics. The incidence of ESBL producing strains of E .coli among clinical isolates have been steadily increasing over the past few years resulting in limitation of therapeutic options. Aim: To detect the ESBL producers in E .coli and determine the antibiotic co resistance of ESBL isolates. Method: The ESBL phenotype was determined by both screening and phenotypic confirmatory methods among different strains of E.coli isolated from clinical samples. The ESBL producing isolates were also studied for the presence of coresistance with other antibiotics. Result: A total of 130 strains of E. coli were isolated from 953 samples. Phenotypic confirmed ESBL production was detected in 82 (63.08%) of the isolates. The maximum number 56 (66.70%) of E. coli isolates from urine were found to be ESBL producers. All the ESBL producing isolates were sensitive to Cefaperazonesulbactam and Imipenem. Among the 82 ESBL producers, 92.68% were resistant to ciprofloxacin, followed by 79.27% to cotrimoxazole, 63.41% to Gentamicin and 20.73% to Amikacin. Conclusion: All ESBL producers were found to be sensitive to Cefaperazonesulbactam and Imipenem. Highest co resistance was found to be with ciprofloxacin and least to Amikacin.
Full Text PDF